Sai Parenteral’s Limited IPO Final Day: GMP ₹0, Subscription 0.4x
As the Initial Public Offering (IPO) of Sai Parenteral’s Limited on the NSE’s mainboard closes today, Day 4, the subscription figures present a mixed picture. With the issue period drawing to a close on March 27, 2026, investors have been evaluating their participation based on the company’s prospects and market sentiment. The issue price has been fixed at ₹392 per share.
Subscription Status
The subscription data for Day 4 reveals varying levels of interest across different investor categories. The Retail Individual Investor (RII) category is showing a low subscription rate of 0.05 times. This suggests a cautious approach from smaller investors, possibly waiting for clearer market signals or finding other investment opportunities more attractive. The Non-Institutional Investor (NII) segment, however, has crossed the mark, standing at 1.01 times. This indicates a healthy interest from high-net-worth individuals and corporate bodies, who often have a longer-term investment horizon and a higher risk appetite. The Qualified Institutional Buyer (QIB) category is currently subscribed at 0.6 times. While not fully subscribed, this level of interest from institutional investors, who conduct extensive due diligence, can be a positive indicator. The overall subscription for the IPO stands at 0.41 times, reflecting the combined interest from all categories.
GMP Update
The Grey Market Premium (GMP) for Sai Parenteral’s Limited IPO remains unchanged at ₹0. Yesterday, the GMP was also reported at ₹0. A GMP of ₹0 suggests that the market is currently not pricing in any significant premium over the issue price for the stock upon listing. This typically implies that the expected listing price is in line with the IPO price of ₹392, and there is no immediate market anticipation of a substantial gain on the debut. The lack of positive GMP might deter some speculative investors looking for quick listing gains.
Should You Apply?
The decision to subscribe to the Sai Parenteral’s Limited IPO requires careful consideration of both the subscription data and the GMP. The NII subscription crossing the book is a positive sign, indicating strong interest from a segment of sophisticated investors. However, the low retail subscription and the flat GMP suggest that the IPO might not be a guaranteed short-term winner. Investors should conduct their own thorough research into the company’s fundamentals, future prospects, and the industry it operates in. As always, it is advisable to consult with a SEBI registered investment advisor before making any investment decisions. The lot size for this IPO is 38 shares.